Apple, Masimo, and most importantly users all suffered from this bizarre legal wrangle. How did it get this far?

Masimo O3®'s delta hemoglobin parameters have received FDA clearance for cerebral and somatic applications and all patient ...

Masimo (Nasdaq: MASI) announced today that it received FDA 510(k) clearance for expanded indications for its O3 regional ...

Masimo ( ($MASI) ) has provided an announcement. On August 18, 2025, William Jellison resigned from the Board of Directors of Masimo Corporation, ...

For nearly two years, Apple Watch users in the United States lived without one of the most popular health features: blood ...

Medical technology company Masimo has been facing off with Apple in court since 2020, and while Masimo has scored some wins, ...

The pulse oximeter maker is now fully operational after a spring cyberattack and increased its 2025 profit forecast, but ...

The company said it would issue a software update to restart the technology, which was caught up in a patent dispute.

Apple will bring back the blood oxygen measurement feature to some of its watch models via a software update after receiving ...

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending ...

Masimo’s share price tumbled 5.2% overnight after Apple announced it would reinstate a blood oxygen measurement feature on ...

Blood oxygen tracking is returning to the Apple Watch after an 18-month hiatus, through a software update effective today.  | ...